Anti-Osteoporosis Therapy and Fracture Healing Market to progress at an impressive 5% CAGR through 2030

Various leading market players are focusing on collaborative product development that has led to product innovation and availability of therapeutic options. For instance, GSK Consumer Healthcare has been established under single business following the completion of the merger of the consumer arms of GSK and Pfizer on August 1 in 2020

Rapidly growing ageing populations and rising prevalence of obesity expected to create considerable growth opportunities. The anti-osteoporosis therapy and fracture healing market is expected to grow significantly in terms of revenue over the forecast period owing to the increase in the availability of technologically advanced products options all over the world.

Moreover, stringent regulations are key restraints affecting growth of anti-osteoporosis therapy and fracture healing market. Side effects caused by osteoporosis drugs such as mild to fatal nausea, skin rashes, and others could affect growth of the market. Stringent regulations imposed by international organizations such as the U.S. Food and Drug Administration, which also conducts frequent revisions of side effects for osteoporosis drugs are challenging anti-osteoporosis therapy and fracture healing market growth.

To remain ‘ahead’ of your competitors, request for a sample

Key Takeaways from Anti-osteoporosis Therapy and Fracture Healing Market Study

Anti-osteoporosis therapy and fracture healing market is expected to register 4.5% Y-o-Y growth in 2021

The demand from the U.S. is expected to be considerably, enabling it to account for a little below 90% of the North America market

The U.K. market is expected to register 5.4% Y-o-Y growth in 2021

France and Germany are likely to exhibit considerably high demand for anti-osteoporosis therapy and fracture healing

Within East Asia, both Japan and South Korea will emerge as key markets

“Increasing prevalence of osteoporosis and rising number of road accidents have fuelled the demand for minimally invasive therapeutics, which is sees as a key market driver. Market players are currently focusing on expanding their distribution channels to strengthen their footprint within the market, while hospital pharmacies continue to remain their preferred channel,” a lead FMI analyst.

Product Launches Remain Key Strategy

Product approvals by the U. S. FDA for anti-osteoporosis therapy and fracture healing drugs as well as injectable are expected to push towards high competition among market players. Numerous companies are focusing on advanced product development that is convenient to use and provide rapid efficacy in the treatment of osteoporosis.

For Instance, in April 2019, Amgen Inc. announced about approval of its EVENITY® by U.S. Food and Drug Administration (FDA) used in the treatment of postmenopausal women at high risk for fracture. According to FMI, oral drugs will continue accounting for the leading market share. Oral will remain highly preferred as route of drug administration, accounting for over 64% of the market in 2021.

Who is winning?

The global market is set to broaden its scope in the forecast period, stimulated by high prevalence rate of osteoporosis, rising geriatric population globally and adoption of advanced anti-osteoporosis therapy and fracture healing products which can be used for long term care needs. In addition to this, changing regulatory dynamics and patent expiry of blockbuster drugs has constrained the sales of anti-osteoporosis therapy and fracture healing products.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1008

The key market players covered by FMI include

• Eli Lilly and Company
• Pfizer, Inc.
• Amgen Inc.
• Merck and Company Inc.
• Novartis International AG
• F. Hoffmann La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline Plc.

consolidating their positions through mergers, acquisitions and new product launches.